Infectious Risks and Complications in Adult Acute Lymphoblastic Leukemia (ALL) Patients Receiving Blinatumomab

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab

© 2016 Harborside Press® Acute lymphoblastic leukemia (ALL) is a rare form of leukemia, with an estimated 6,250 new cases diagnosed in the United States in 2015 and approximately 1,450 deaths (American Cancer Society, 2015). With current available induction therapies, complete remission (CR) rates in adults are approximately 75% to 90% (Faderl et al., 2010; Bassan & Hoelzer, 2011). After induct...

Acute Lymphoblastic Leukemia (ALL)

IMMUNOLOGICAL PHENOTYPING OF ACUTE LYMPHOBLASTIC LEUKEMIA ( ALL) IN UNIVERSITY AFFILIATED HOSPITALS: A PRELIMINARY REPORTON 50 PATIENTS

The peripheral blood and bone marrow samples from 50 patients with ALL were investigated by indirect immunofluorescent technique. The most common type of ALL was common-ALL (82%) and the least common was T-ALL (2%). Other subtypes of ALL were unclassified by our technique (8%), B-ALL (4%), and pre B-ALL (4%). The correlation between immunophenotype, clinical condition and hematological pro...

Bone Density in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL): A Literature Review

Introduction:  Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children and the main form of childhood leukemia (75%). ALL different treatment options have a great impact on children weight and appetite. The improving prognosis for children with cancer refocuses attention to long-term outcomes with an emphasis on quality of life. More survival rate allows researchers to eval...

Adult Acute Lymphoblastic Leukemia.

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) results in high cure rates in pediatric patients but is suboptimal in the treatment of adult patients. The 5-year overall survival is approximately 90% in children and 30% to 40% in adults and elderly patients. Adults with ALL tend to have higher risk factors at diagnosis, more comorbidities, and increasing age...